After TACTI-004's Phase III failure, Immutep's investment case rests on whether IMP761 can establish proof-of-concept in autoimmune disease from a Phase I starting point

Bull

A positive MAD readout would show clean pharmacokinetics with predictable exposure across dose levels, sustained T-cell suppression consistent with the SAD signal (statistically significant skin blood perfusion reduction and durable intradermal T-cell inhibition), and no cumulative or dose-limiting toxicities. This would validate IMP761 as a first-in-class LAG-3 agonist capable of restoring immune tolerance, justify advancement into a disease-specific Phase II in a named autoimmune indication, and provide Immutep with a credible new lead program to anchor a rebuilt investment thesis.

Bear

The most likely failure modes are toxicity signals that emerge with repeat dosing — autoimmune paradox effects, cytokine release, or off-target immunosuppression — that were absent in the SAD but become apparent at therapeutic exposures required for chronic autoimmune disease management. Alternatively, pharmacokinetic variability or insufficient target engagement at the two MAD dose levels could produce an ambiguous immunosuppressive signal that neither de-risks nor progresses the program, leaving the company without a clear path to Phase II and stranding the thesis at the earliest possible data point.